Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13871095 | 0.87 | NPC1 (0.36) | NPC1 | |
| SCHEMBL5667822 | 0.86 | NPC1 (0.36) | NPC1 | |
| SCHEMBL13866135 | 0.85 | NPC1 (0.39) | NPC1HSD17B14MAPT | |
| SCHEMBL13866114 | 0.85 | CFTR (0.38) | NPC1MAPT | |
| SCHEMBL5667000 | 0.85 | NPC1 (0.41) | NPC1MAPT | |
| SCHEMBL13866070 | 0.78 | NPC1 (0.36) | NPC1 | |
| SCHEMBL14193452 | 0.78 | NPC1 (0.37) | NPC1CASR | |
| SCHEMBL5668925 | 0.77 | NPC1 (0.39) | NPC1MAPT | |
| SCHEMBL14193600 | 0.76 | NPC1 (0.36) | NPC1HSD17B14 | |
| SCHEMBL13871097 | 0.76 | NPC1 (0.38) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148224-B2 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-12 | — | — | US | disclosed |
| US-20050176719-A1 | Novel pyrazinone derivatives | MSD K.K. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6914062-B2 | Pyrazinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-05 | — | — | US | disclosed |
| EP-1295878-B1 | PYRAZINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-20030203907-A1 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | MSD K.K. (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1295878-A1 | NOVEL PYRAZINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203907-A1 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | CDK4, CDK6, CCNI | NPC1 4328/4885TLR8 4648/4885HSD17B14 883/4885 |
| US-20050176719-A1 | Novel pyrazinone derivatives | CDK6, CDK4, CDK16 | NPC1 4126/4885TLR8 4093/4885HSD17B14 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.